b. addition of water (0.3 to 0.7 vol.) at 45 to 60°C;
c. stirring of the mixture under cooling from a temperature of 45 to 60°C to a temperature at or below 30°C for at least 1h; and
d. isolation of the obtained crystalline material.

10. A process according to claim 9, wherein the amount of the non-polar solvent in step a. is 1.0 to 2.0 vol. and wherein the non-polar solvent is dichloromethane.

11. A process according to any one of claims 9 or 10, wherein the mixture is stirred in step c. between 1 and 4h at a temperature of 45 to 60°C and is subsequently cooled to a temperature between 20 and 30°C during 1 to 2h.

12. A crystalline form of 4-((*R*)-2-{[6-((*S*)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride according to any one of claims 1 to 8, for use as a medicament.

13. A pharmaceutical composition comprising as active ingredient a crystalline form of 4-((*R*)-2-{[6-((*S*)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride according to any one of claims 1 to 8, and at least one pharmaceutically acceptable carrier.

14. A crystalline form of 4-((*R*)-2-{[6-((*S*)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride according to any one of claims 1 to 8, for use in the manufacture of a pharmaceutical composition, wherein said pharmaceutical composition comprises as active ingredient 4-((*R*)-2-{[6-((*S*)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride, and at least one pharmaceutically acceptable carrier material.

15. A crystalline form of 4-((*R*)-2-{[6-((*S*)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride according to any one of claims 1 to 8, for use in the prevention or treatment of diseases selected from the group consisting of of acute coronary syndromes, peripheral ischaemia, amaurosis, ischaemic stroke and transient ischaemic attack.

16. Use of 4-((*R*)-2-{[6-((*S*)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention or treatment of a disease selected from the group consisting of of acute coronary syndromes, peripheral ischaemia, amaurosis, ischaemic stroke and transient ischaemic attack, wherein 4-((*R*)-2-{[6-((*S*)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-

carboxylic acid butyl ester, or a pharmaceutically acceptable salt thereof, is obtained from a crystalline form of 4-((*R*)-2-{[6-((*S*)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride according to any one of claims 1 to 8.

17. Use of a crystalline form of 4-((*R*)-2-{[6-((*S*)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride according to any one of claims 1 to 8, in the manufacture of a pharmaceutical composition for the prevention or treatment of diseases selected from the group consisting of acute coronary syndromes, peripheral ischaemia, amaurosis, ischaemic stroke and transient ischaemic attack.